These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 37875627)

  • 1. Tau-targeting therapies for Alzheimer disease: current status and future directions.
    Congdon EE; Ji C; Tetlow AM; Jiang Y; Sigurdsson EM
    Nat Rev Neurol; 2023 Dec; 19(12):715-736. PubMed ID: 37875627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau-targeting therapies for Alzheimer disease.
    Congdon EE; Sigurdsson EM
    Nat Rev Neurol; 2018 Jul; 14(7):399-415. PubMed ID: 29895964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation.
    Ashrafian H; Zadeh EH; Khan RH
    Int J Biol Macromol; 2021 Jan; 167():382-394. PubMed ID: 33278431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological changes induced by Alzheimer's brain inoculation in amyloid-beta plaque-bearing mice.
    Lam S; Hérard AS; Boluda S; Petit F; Eddarkaoui S; Cambon K; ; Picq JL; Buée L; Duyckaerts C; Haïk S; Dhenain M
    Acta Neuropathol Commun; 2022 Aug; 10(1):112. PubMed ID: 35974399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
    Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
    Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invited Review - Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials.
    Boche D; Nicoll JAR
    Neuropathol Appl Neurobiol; 2020 Dec; 46(7):623-640. PubMed ID: 32643143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
    Boutajangout A; Wisniewski T
    Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
    Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM
    Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease.
    Madav Y; Wairkar S; Prabhakar B
    Brain Res Bull; 2019 Mar; 146():171-184. PubMed ID: 30634016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Status and future directions of clinical trials in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical analysis of the 'amyloid cascade hypothesis'.
    Armstrong RA
    Folia Neuropathol; 2014; 52(3):211-25. PubMed ID: 25310732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial model of amyloid β and tau reveals synergy between amyloid deposits and tangle formation.
    Koller EJ; Ibanez KR; Vo Q; McFarland KN; Gonzalez De La Cruz E; Zobel L; Williams T; Xu G; Ryu D; Patel P; Giasson BI; Prokop S; Chakrabarty P
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12779. PubMed ID: 34825397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease.
    Morris GP; Clark IA; Vissel B
    Acta Neuropathol Commun; 2014 Sep; 2():135. PubMed ID: 25231068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau immunotherapies for Alzheimer's disease.
    Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B
    Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation.
    Luan K; Rosales JL; Lee KY
    Ageing Res Rev; 2013 Jan; 12(1):174-81. PubMed ID: 22728532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.